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NUCLEOTIDE (DNA) SEQUENCE FOR crnws VALENCENE SYNTHASE
GENE (CVS)
SEQ ID NO.: 1
LENGTH: 1710 NT

64

ATGTCGTCTGGAGAAACATTTCGTCCTACTGCAGATTTCCATCCT

109

AGTTTATGGAGAAACCATTTCCTCAAAGGTGCTTCTGATTTCAAG

154

ACAGTTGATCATACTGCAACTCAAGAACGACACGAGGCACTGAAA

199

GAAGAGGTAAGGAGAATGATAACAGATGCTGAAGATAAGCCTG TT

244
289
334
379
424
469
514
559
604
649
694
739
784
829

CAGAAGTTACGCTTGATTGATGAAGTACAACGCCTGGGGGTGGCT
TATCACTTTGAGAAAGAAATAGAAGATGCAATACTAAAATTATGT
CCAATCTATATTGACACTAATAGAGCTGATCTCCACACCGTTTCC
CTTCATTTTCGATTGATTAGGCAGCAAGGAATCAAGATTTCATGT
GATGTGTTTGAGAAGTTCAAAGATGATGAGGGTAGATTCAAGTCA
TCGTTGATAAACGATGTTCAAGGGATGTTAAGTTTGTACGAGGCA
GCATACATGGCAGTTCGCGGAGAACATATATTAGATGAAGCCATT
GCTTTCACTACCACTCACCTGAAGTCATTGGTAGCTCAGGATCAT
GTAACCCCTAAGCTTGCGGAACAGATAAATCATGCTTTATACCGT
CCTCTTCGTAAAACCCTACCAAGATTAGAGGCGAGGTATTTTATG
TCCATGATCAATTCAACAAGTGATCATTTATACAATAAAACTCTG
CTGAATTTTGCAAAGTTAGATTTTAACATATTGCTAGAGCCGCAC
AAGGAGGAACTCAATGAATTAACAAAGTGGTGGAAAGATTTAGAC

974

TTCACTACAAAACTACCTTATGCAAGAGACAGATTAGTGGAGTTA
TAZTTTTGGGATTTAGGGACATACTTCGAGCCTCAATATGCATTT

919
964
1009
1054
1099
1144

GGGAGAAAGATAATGACCCAATTAAATTACATATTATCCATCATA
GATGATACTTATGATGCGTATGGTACACTTGAAGAACTCAGCCTC
TTTACTGAAGCAGTTCAAAGATGGAATATTGAGGCCGTAGATATG
CTTCCAGAATACATGAAATTGATTTACAGGACACTCTTAGATGCT
TTTAATGAAATTGAGGAAGATATGGCCAAGCAAGGAAGATCACAC
TGCGTACGTTATGCAAAAGAGGAGAATCAAAAAGTAATTGGAGCA

1189
1234
1279
1324
1369
1414

TACTCTGTTCAAGCCAAATGGTTCAGTGAAGGTTACGTTCCAACA
ATTGAGGAGTATATGCCTATTGCACTAACAAGTTGTGCTTACACA
TTCGTCATAACAAATTC'CTTCCTTGGCATGGG'IGATTTTGCAACT
AAAGAGGTTTTTGAATGGATCTCCAATAACCCTAAGGTGTTAAAA
GCAGCATCAGTTATCTGCAGACTCATGGATGACATGCAAGGTCAT
GAGTTTGAGCAGAAGAGAGGACATGTTGCGTCAGCTATTGAATCT

1459
1504
1549
1594
1639

TACACGAAGCAGCATGGTGTOTCTAAGGAAGAGGCAATTAAAATG
TTTGAAGAAGAAGTTGCAAATGCATGGAAAGATATTAACGAGGAG
TTGATGATGAAGCCAACCGTCGTTGCCCGACCACTGCTCGGGACG
ATTCTTAATCTTGCTCGTGCAATTGATTTTATTTACAAAGAGGAC
GACGGCTATACGCATTCTTACCTAATTAAAGATCAAATTGCTTCT
G TGC TAGGAGACCACGT TCCAT T T TGA

1710
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AMlNO ACID SEQUENCE OF CITRUS VALENCENE SYNTHASE (CV5)
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SESQUITERPENE SYNTHASE GENE AND

reduced pressure is de?ned as the extraction pressure of the

PROTEIN

solvent gas divided by its critical pressure), to extract ?avor
and aroma compounds; (b) separating the solvent gas and
dissolved compounds from the remaining undissolved com

RELATED APPLICATIONS

pounds; and (c) separating the dissolved compounds from the
solvent gas.
Rich, in US. Pat. No. 4,973,485, discloses a method of

This application is a continuation of allowed US. patent

application Ser. No. 12/259,497, ?led Oct. 28, 2008, which
claims bene?t of priority under 35 U.S.C. 120 to US. patent
application Ser. No. 10/899,356, ?led on Jul. 26, 2004, now
US. Pat. No. 7,442,785, issued Oct. 28, 2008, which claims
bene?t of priority under 35 U.S.C. 119(e) to US. Provisional

producing aqueous orange stripper essences and orange strip
per oils with high ratios of valencene to the less desirable
orange ?avor compounds. This procedure involves the fol
lowing steps: (a) heating an orange fed juice stream to a
temperature of 37.7° C. to 71 ° C.; (b) stripping the heated feed

Application No. 60/489,514, ?led Jul. 24, 2003. The disclo
sures of the above referenced applications are incorporated by
reference in their entirety herein.

juice with steam at a steam: soluble solids ratio of 0.3 to 1.5, at
a temperature of 37.7° C. to 71° C. and at a stripping column

FIELD OF THE INVENTION

the stripped volatiles at a temperature of 406° C. to —196° C.;
(d) centrifuging the condensate in a continuous stacked disk

This invention relates generally to the ?eld of production of
valencene and nootkatone, and more particularly relates to
the discovery of a valencene synthase gene and related pro

pressure of less than 9 inches of Hg, absolute; (c) condensing

hermetic centrifuge to produce two clear phases; and (e)
removing the aqueous orange stripper essence phase.
In US. Pat. No. 5,260,086 Downton et al. describe a pro
20

cess for making an aseptic citrus sensible pulp/juice slurry by

extracting and removing juice from citrus juice containing

tein, which provides a pathway for generating highly pure
valencene which can be converted into the ?avorant, nootka

sensible pulp. After this process is complete, ?avorants, such

tone.

as valencene are added to make up for those that are lost

during this extraction process.
BACKGROUND

25

Terpenes are a diverse family of compounds with carbon

hydrate alcohol solvent extraction. To maintain the stability
of the ?avor, a stabiliZing coumarin analogue component is

skeletons composed of ?ve-carbon isoprene units. Approxi
mately 20,000 different terpenes and terpenoids (compounds
of terpene origin whose carbon skeleton has been altered or

30

added.
In a US patent application, publication number US

35

20030185956, Gradley claims a separation method for
extracting desired sesquiterpene aroma compounds, such as
valencene and nootkatone, from an aqueous phase by sepa
rating the aqueous mixture from a water-immiscible hydro
phobic phase by means of a hydrophilic membrane and allow

rearranged) have been identi?ed to date, representing only a
small fraction of the estimated natural variation. Terpenes are
commonly isolated from the essential oils of plants. Essential
oils often have pleasant tastes or aromas, and they are widely
used as ?avorings, deodorants, and medicines.
Sesquiterpenes are terpenes with 15 carbon atoms (three

Hiramoto et al., in US. Pat. No. 6,495,193 prepares a citrus
?avor from a low-boiling part of a cold pressed oil by a

ing the desired components to move out off the aqueous phase

isoprene units). The plant kingdom contains the highest diver

through the membrane and into the hydrophobic phase.

sity of sesquiterpenes. Often they play a role in defense of the
plants against pathogens, insects and herbivores and for
attraction of pollinating insects.

Kotachi et al., in US patent application, publication num
ber 20030203090, teaches of a process for preparing orange
oil useful as fragrance or ?avor material, by mixing raw
material oil containing valencene with a high-boiling solvent

40

Valencene (1 ,2,3,5,6,7,8,8a-octahydro-7-isopropenyl-1,
8a-dimethyl-naphthalene) and nootkatone (4,4a,5,6,7,8

having a boiling point exceeding 240° C. under normal pres
sure, to give a mixture, and fractionally distilling the mixture

hexahydro-6-isopropenyl-4,4-a-dimethyl-2(3H)-naphtal
enone) are just two examples of sesquiterpenes that are

derived from cyclization of the ubiquitous pyrophosphate
intermediate farnesyl diphosphate. Nootkatone is formed by

45

the oxidation of valencene.
Valencene and nootkatone are compounds of natural ori
gin, and are natural constituents of citrus oils, such as orange

and grapefruit. Because of its excellent organoleptic qualities
and in particular its typical grapefruit taste, nootkatone is a
widely used ingredient in perfumery and the ?avor industry.

rently, the practice of extracting nootkatone from citrus pulp
50

easily degraded during evaporative heat concentration pro
feed juice. Thus, current methods to purify valencene from
citrus fruits are costly, di?icult, and are limited by what the

Valencene, the starting material for the generation of nootka
55

?avorant and fragrance.
Several methods to purify sesquiterpenes, such as valen
cene and nootkatone, from citrus fruits or to maintain high
levels of these sesquiterpenes in citrus fruit extracts have been
described in the prior art. These methods are described below.
Japikse et al., in US. Pat. No. 4,693,905, claimed a method
of extracting concentrated orange ?avor and aroma compo
sitions from natural orange essence oil by using a dense

between its critical temperature and 100° C., and having a
reduced pressure between about 0.56 and about 1.31 (where

fruit can deliver. Moreover, such methods are vulnerable to

interruptions in the supply of citrus fruits, which is dependent
on the weather. A frost or hailstorm in a major citrus fruit

60

growing region such as Florida can interrupt the supply. Fur
thermore, methods to produce nootkatone that consume
valencene are quite costly, and thus not commercially desir
able. Therefore, there is a need for an alternative means for

preparing valencene and nootkatone.

solvent gas. Their procedure entailed (a) contacting natural
orange essence oil with a solvent gas having a temperature

and rind is considered an expensive and somewhat unreliable
process. Nootkatone can be synthesized by the oxidation of
valencene. The valencene starting material is expensive and is
cesses typically used to remove the bulk of water from the

Alternatively, nootkatone may be used as an insecticide.

tone (either biologically or chemically), is also used as a

obtained.
Nootkatone is a high demand, high value ?avorant added to
many of the commercial soft drinks sold worldwide. Cur

SUMMARY OF THE INVENTION
65

In one embodiment, the invention relates to isolated

nucleic acids that encode a sesquiterpene synthase. The

US 8,835,131 B2
3

4

invention provides an isolated nucleic acid selected from: (a)
a nucleic acid comprising the nucleotide sequence substan
tially as set out in SEQ ID NO: 1; (b) a nucleic acid encoding

stringency conditions, wherein the polypeptide encoded by
said nucleic acid is a sesquiterpene synthase. The host may be

chosen from, for example, plants, microorganisms, bacterial
cells, yeast cells, plant cells, and animal cells.

the polypeptide substantially set out in SEQ ID NO: 4; and (c)
a nucleic acid that hybridizes to the nucleic acid of (a) or (b)

In another embodiment the invention provides a method of

under low stringency conditions, wherein the polypeptide

making at least one terpenoid comprising:
1) contacting at least one acyclic pyrophosphate terpene pre

encoded by said nucleic acid is a sesquiterpene synthase.
Other embodiments include: a polypeptide encoded by a
nucleic acid of the invention; a host cell comprising a nucleic
acid of the invention; a non-human organism modi?ed to
harbor a nucleic acid of the invention; and methods of pro

cursor with at least one polypeptide encoded by a nucleic
acid of the current invention. In one embodiment, the

nucleic acid is chosen from (a) a nucleic acid comprising
the nucleotide sequence substantially as set out in SEQ ID
NO: 1, SEQ ID NO: 5 or SEQ ID NO: 6; (b) a nucleic acid

ducing a polypeptide comprising culturing host cells of the
invention.
In another embodiment, the invention provides an isolated

encoding the polypeptide substantially set out in SEQ ID
NO: 4, SEQ ID NO: 7 or SEQ ID NO: 8; and (c) a nucleic
acid that hybridizes to the nucleic acid of (a) or (b) under

polypeptide comprising an amino acid sequence substantially
as set out in SEQ ID NO: 4.
In a further embodiment, the invention provides a vector
comprising at least one nucleic acid chosen from (a) a nucleic

acid comprising the nucleotide sequence substantially as set
out in SEQ ID NO: 1; (b) a nucleic acid encoding the polypep
tide substantially set out in SEQ ID NO: 4; and (c) a nucleic
acid that hybridizes to the nucleic acid of (a) or (b) under low

low stringency conditions, wherein the polypeptide
encoded by said nucleic acid is a sesquiterpene synthase,
2) isolating at least one terpenoid produced in 1).
In one embodiment, the at least one terpenoid is chosen
20

In a further embodiment, the at least one acyclic pyrophos

phate terpene precursor is famesyl-diphosphate (FPP). The
sesquiterpene produced by the methods of the invention

stringency conditions, wherein the polypeptide encoded by
said nucleic acid is a sesquiterpene synthase. Other embodi
ments include, methods of making a recombinant host cell
comprising introducing a vector of the invention into a host
cell.
In a further embodiment, the invention relates to isolated
nucleic acids that encode a sesquiterpene synthase. The
invention provides an isolated nucleic acid selected from: (a)
a nucleic acid comprising the nucleotide sequence substan
tially as set out in SEQ ID NO: 5 or SEQ ID NO: 6; (b) a

include, but are not limited to, valencene, valencene deriva
25

BRIEF DESCRIPTION OF THE DRAWINGS
30

35

FIG. 2 illustrates a mechanism for the enzyme catalyzed

40

Two additional chiral centers develop upon formation of an
internal bond between C2 and C7. This process of proton

In another embodiment, the invention provides an isolated

polypeptide comprising an amino acid sequence substantially
45

50

initiated, internal cyclization (illustrated as transition states)
requires that the p-orbitals of sp2 hybridized C2 and C7 face
and align with each other. The 4 possible combinations of
overlapping orbitals are dependent on the orientation of the
respective p orbitals either above or below the plane of the
eudesmalyl carbocation intermediate. The possible re and si
orientations of the C2 p-orbitals are given on the vertical axis
of the diagram and those for C7 depicted on the horizontal
axis. These orientations direct the stereochemistry of the

ensuing methyl migrations and hydride shifts (not illustrated)
55

invention into a host cell.

In one embodiment, the invention provides a method of

making at least one sesquiterpene synthase comprising cul
turing a host cell modi?ed to contain at least one nucleic acid

sequence under conditions conducive to the production of
said at least one sesquiterpene synthase. In one embodiment,
the at least one nucleic acid is chosen from (a) a nucleic acid
comprising the nucleotide sequence substantially as set out in
SEQ ID NO: 1, SEQ ID NO: 5 or SEQ ID NO: 6; (b) a nucleic

60

acid encoding the polypeptide substantially set out in SEQ ID

65

NO: 4, SEQ ID NO: 7 or SEQ ID NO: 8; and (c) a nucleic acid
that hybridizes to the nucleic acid of (a) or (b) under low

tion of the initial carbocation, a chiral center arises from the
?rst attack on either the si or re face of sp2 hybridized C10

yielding either (10R)-germacrene A or (10S)-germacrene A.

invention; and methods of producing a polypeptide compris
ing culturing host cells of the invention.

SEQ ID NO: 5 or SEQ ID NO: 6; (b) a nucleic acid encoding
the polypeptide substantially set out in SEQ ID NO: 7 or SEQ
ID NO: 8; and (c) a nucleic acid that hybridizes to the nucleic
acid of (a) or (b) under low stringency conditions, wherein the
polypeptide encoded by said nucleic acid is a sesquiterpene
synthase. Other embodiments include, methods of making a
recombinant host cell comprising introducing a vector of the

(CVS), respectively.
development of regio- and enantio-speci?city in eremo
philanes. Upon loss of the diphosphate from C1 and genera

nucleic acid is a sesquiterpene synthase. Other embodiments
include: a polypeptide encoded by a nucleic acid of the inven

as set out in SEQ ID NO: 7 or SEQ ID NO: 8.
In a further embodiment, the invention provides a vector
comprising nucleic acid chosen from (a) a nucleic acid com
prising the nucleotide sequence substantially as set out in

FIG. 1 shows the conversion of FPP to the sesquiterpene

reaction products 5-epi-aristolochene, premnaspirodiene and
valencene catalyzed by Nicotiana tabacum epi-aristolochene
synthase (TEAS), Hyoscyamus mulicus premnaspirodiene
synthase (HPS), and Citrus paradisi valencene synthase

gency conditions, wherein the polypeptide encoded by said
tion; a host cell comprising a nucleic acid of the invention; a
non-human organism modi?ed to harbor a nucleic acid of the

tives, valencene fragments, and compounds having the citrus
valencene carbon skeleton.

nucleic acid encoding the polypeptide substantially set out in
SEQ ID NO: 7 or SEQ ID NO: 8; and (c) a nucleic acid that
hybridizes to the nucleic acid of (a) or (b) under low strin

from the group consisting of sesquiterpene.

and de?ne, as a consequence, the ?nal chirality of the methyl
substitutions at C2 and C3. Subsequent to these rearrange
ments, a tertiary carbocation centered at C7 is formed (an
eremophilyl cation, not shown) and alternate elimination of a
proton from C6 or C8 give two subclasses of double bond
regioisomers, illustrated as layers. Known eremopliilanes are
noted by their common name.

FIG. 3 illustrates a proposed pathway for the biosynthesis
of nootkatone in citrus. The scheme suggests at least two

steps, the ?rst step is catalyzed by the sesquiterpene synthase
of the current invention, denoted as “1” in the ?gure, which
leads to the production of valencene and the second step

consisting of a regio-speci?c hydroxylation, followed by oxi
dation. The second step could be catalyzed by a single mul

US 8,835,131 B2
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tifunctional hydroxylase or could involve sequential enzyme

FIG. 1411 shows the absolute amino acid sequence from
SEQ ID NO: 4 corresponding to the Tier 1 amino acid resi
dues. FIG. 14b shows the comparative amino acid sequence

mediated reactions, and which are denoted as “2” in the

?gure.

of the Tier 1 amino acid residues (SEQ ID NO: 7).

FIG. 4 illustrates a sequence alignment of amino acids

FIG. 1511 shows the absolute amino acid sequence from
SEQ ID NO: 4 corresponding to Tier 2 amino acid residues.
FIG. 15b shows the comparative amino acid sequence of the
Tier 2 amino acid residues (SEQ ID NO: 8).
FIG. 16 is a sequence alignment of the amino acid
sequence of TEAS active site compared to the amino acid
sequence of the CVS active site. The alignment maximizes
residue similarities and introduce gaps where necessary.
Absolute amino acid numbering is shown for CVS, thus
amino acid numbering from SEQ ID NO: 4 is shown for CVS.
FIG. 17 is a chart showing the TEAS Tier 1 and Tier 2
amino acid residues in column 1; the CVS Tier 1 and Tier 2
amino acid residues with absolute numbering in column 2;
and the CVS Tier 1 and Tier 2 amino acid residues with

lining the active site (1st tier) and those within 3 A of the
active site residues (2nd tier) of TEAS with the corresponding
positions of CVS. For uniformity, the TEAS amino acids
numbering was used, and thus the corresponding CVS amino
acids renumbereditermed comparative numbering. The 1st
tier residues lie within 3 A of a substrate analog co-crystal
lized within the TEAS enzyme and includes residues making
up the J/ K loop which clamps down over the active site upon

substrate binding. The corresponding residues within CVS

(valencene synthase) were initially identi?ed by primary
sequence alignment, then visual inspection of the relevant
CVS sequences overlaid on the TEAS 3-dimensional struc
ture. Residues different from TEAS are highlighted.

FIG. 5 shows SEQ ID NO: 1, which is the DNA sequence
for the citrus valencene synthase gene from Citrus paradis

comparative numbering in column 3.
20

isolated in the current invention.

FIG. 6 shows SEQ ID NO: 4, which is the protein sequence
for the citrus valencene synthase from Citrus paradisi.
FIG. 7 illustrates reaction product analysis of citrus valen
cene synthase (CVS) incubated at pH 7.5. Lysate of E. coli

DETAILED DESCRIPTION OF THE INVENTION

Abbreviations and Terms
25

expressing the CVS cDNA was incubated with FPP at pH 7.5

the following meanings, unless explicitly stated otherwise.
These explanations are intended to be exemplary only. They

and total pentane extractable products evaluated by GC-MS
(upper panel). The mass spectrum of the reaction product
corresponding to peakA (middle panel) is compared to that of
authentic valencene in the lower panel. The mass spectrum of
peak B is identical to that for beta-elemene, the thermal

are not intended to limit the terms as they are described or
30

FIG. 8 illustrates a mass spectrum for the peak with a

retention time of 7.38 minutes from FIG. 7 (top) compared to
35

(bottom).
FIG. 9 illustrates mass spectrum for the peak with a reten

tion time of 8.89 in FIG. 7 (top) compared to that for valen
cene purchased from Fluka Chemical Company (bottom).
FIG. 10 illustrates that the reaction product speci?city of

referred to throughout the speci?cation. Rather, these expla
nations are meant to include any additional aspects and/or

induced rearrangement product of germacrene A.

the spectra for beta-elemene published by the NIST library

In accordance with the present invention and as used
herein, the following terms and abbreviations are de?ned with

examples of the terms as described and claimed herein.
The following abbreviations are used herein:
As used herein, a “derivative” is any compound obtained
from a known or hypothetical compound and containing
essential elements of the parent substance.
The phrase “substantially identical” means that a relevant

sequence is at least 70%, 75%, 80%, 85%, 90%, 92%, 95%
40

citrus valencene synthase (CVS) is pH dependent. Partially

96%, 97%, 98%, or 99% identical to a given sequence. By
way of example, such sequences may be allelic variants,
sequences derived from various species, or they may be

puri?ed synthase isolated from E. coli expressing the CVS

derived from the given sequence by truncation, deletion,

cDNA was incubated with FPP at the indicated pH values and

amino acid substitution or addition. Percent identity between

ethylacetate extracts were examined directly by GC-MS.
Absolute values for valencene (solid symbols) and germa
crene A (measured as the thermally rearranged product [3-el

two sequences is determined by standard alignment algo
45

rithms such as ClustalX when the two sequences are in best

alignment according to the alignment algorithm.

emene) (open symbols) are reported and represent greater

As used herein, the term “hybridization” or “hybridizes”

than 95% of the total reaction products at all pHs.
FIG. 11 is a sequence alignment of amino acids lining the

under certain conditions is intended to describe conditions for

active site (1 st tier) of TEAS with the corresponding positions

hybridization and washes under which nucleotide sequences
50

of HPS and CVS. The 1st tier residues lie within 3 A of a

substrate analog co-crystallized within the TEAS enzyme and
includes residues making up the J/ K loop which clamps down
over the active site upon substrate binding. The correspond
ing residues within the other terpene synthases were initially

experimentation as exempli?ed in Ausubel, F. A., et al., eds.,
Current Protocols in Molecular Biology Vol. 2, John Wiley
55

identi?ed by primary sequence alignment, then visual inspec

ing: A Laboratory Manual, 2nd ed., Cold Spring Harbor
Laboratory Press, New York (1989). Variations on the condi
tions for low, moderate, and high stringency are well known

highlighted.
ing Tier 1. Comparative numbering from Tier 1 amino acid
residues is also shown (SEQ ID NO: 7).
FIG. 13 shows SEQ ID NO: 6, which is the DNA sequence
from SEQ ID NO: 1 corresponding to the amino acids form
ing Tier 2. Comparative numbering from Tier 2 amino acid
residues is also shown (SEQ ID NO: 8).

and Sons, Inc., New York (1995). Additionally, stringency
conditions are described in Sambrook et al. Molecular Clon

tion of the relevant sequences overlaid on the TEAS 3 -dimen
sional structure. Residues in CVS differing from TEAS are

FIG. 12 shows SEQ ID NO: 5, which is the DNA sequence
from SEQ ID NO: 1 corresponding to the amino acids form

that are signi?cantly identical or homologous to each other
remain bound to each other. Appropriate hybridization con
ditions can be selected by those skilled in the art with minimal

60

in the art and may be used with the current invention.
The terms “nucleic acid” or “nucleic acid molecule” refer
to a deoxyribonucleotide or ribonucleotide polymer in either

single- or double-stranded form, and unless otherwise lim
ited, would encompass known analogs of natural nucleotides
65

that can function in a similar manner as naturally occurring

nucleotides. A “nucleotide sequence” also refers to a poly
nucleotide molecule or oligonucleotide molecule in the form

US 8,835,131 B2
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of a separate fragment or as a component of a larger nucleic
acid. The nucleotide sequence or molecule may also be
referred to as a “nucleotide probe.” Some of the nucleic acid
molecules of the invention are derived from DNA or RNA
isolated at least once in substantially pure form and in a

polypeptide within the scope of the invention is de?ned as an
amino acid sequence comprising a linear or 3-dimensional

sequences of the invention. Alternatively, a polypeptide
within the scope of the invention is recognized by an antibody

quantity or concentration enabling identi?cation, manipula

that speci?cally recognizes any peptide encoded by the

tion, and recovery of its component nucleotide sequence by
standard biochemical methods. Examples of such methods,
including methods for PCR protocols that may be used

nucleic acid sequences of the invention. Antibodies are

epitope shared with any peptide encoded by the nucleic acid

de?ned to be speci?cally binding if they bind polypeptides of
the invention with a K, of greater than or equal to about
107M_l, such as greater than or equal to 108M_l. As used
herein, the term “isolated,” in reference to polypeptides or
proteins, means that the polypeptide or protein is substan

herein, are disclosed in Sambrook et al. Molecular Cloning: A

Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory
Press, New York (1989), Ausubel, F. A., et al., eds., Current
Protocols in Molecular Biology, John Wiley and Sons, lnc.,
NewYork (1987), and Innis, M., et al. (Eds.) PCR Protocols:

tially removed from polypeptides, proteins, nucleic acids, or

A Guide to Methods and Applications, Academic Press, San
Diego, Calif. (1990). Reference to a nucleic acid molecule
also includes its complement as determined by the standard

require a speci?c degree of purity, typically, the protein will

other macromolecules with which it, or its analogues, occurs
in nature. Although the term “isolated” is not intended to
be at least about 75% pure, more typically at least about 90%
pure, preferably at least about 95% pure, and more preferably
at least about 99% pure.

Watson-Crick base-pairing rules, with uracil (U) in RNA

replacing thymine (T) in DNA, unless the complement is
speci?cally excluded.
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tide, but which has an amino acid sequence different from that
encoded by any of the nucleic acid sequences of the invention

stranded form, as well as the DNA or RNA complement

thereof. DNA includes, for example, DNA, genomic DNA,
chemically synthesized DNA, DNA ampli?ed by PCR, and
combinations thereof. Genomic DNA, including translated,

because of one or more deletions, insertions or substitutions.
25

non-translated and control regions, may be isolated by con
ventional techniques, e. g., using any one of the cDNAs of the
invention, or suitable fragments thereof, as a probe, to iden

tify a piece of genomic DNA which can then be cloned using
methods commonly known in the art.

A polypeptide “variant” as referred to herein means a

polypeptide substantially homologous to a native polypep

As described herein, the nucleic acid molecules of the
invention include DNA in both single-stranded and double

Variants can comprise conservatively substituted sequences,
meaning that a given amino acid residue is replaced by a
residue having similar physiochemical characteristics. See

Zubay, Biochemistry, Addison-Wesley Pub. Co., (1983). It is
a well-established principle of protein and peptide chemistry
30

Polypeptides encoded by the nucleic acids of the invention
are encompassed by the invention. As used herein, reference

that certain amino acids substitutions, entitled “conservative”
amino acid substitutions, can frequently be made in a protein
or a peptide without altering either the con?rmation or the
function of the protein or peptide. Such changes include

assumption that the introns included have appropriate splice

substituting any of isoleucine (I), valine (V), and leucine (L)
for any other of these amino acids; aspartic acid (D) for
glutamic acid (E) and vice versa; glutamine (Q) for aspar
agine (N) and vice versa; and serine (S) for threonine (T) and

donor and acceptor sites that will ensure that the introns are

vice versa.

to a nucleic acid “encoding” a protein or polypeptide encom

passes not only cDNAs and other intronless nucleic acids, but
also DNAs, such as genomic DNA, with introns, on the

spliced out of the corresponding transcript when the tran
script is processed in a eukaryotic cell. Due to the degeneracy

35

40

of the genetic code wherein more than one codon can encode
the same amino acid, multiple DNA sequences can code for
the same polypeptide. Such variant DNA sequences can result

depending on the environment of the particular amino acid.

For example, glycine (G) and alanine (A) can frequently be

from genetic drift or arti?cial manipulation (e.g., occurring
during PCR ampli?cation or as the product of deliberate
mutagenesis of a native sequence). Deliberate mutagenesis of

The above-mentioned substitutions are not the only amino
acid substitutions that can be considered “conservative.”
Other substitutions can also be considered conservative,

interchangeable, as can be alanine and valine (V). Methionine
45

(M), which is relatively hydrophobic, can frequently be inter
changed with leucine and isoleucine, and sometimes with

a native sequence can be carried out using numerous tech

valine. Lysine (K) and arginine (R) are frequently inter

niques well known in the art. For example, oligonucleotide
directed site-speci?c mutagenesis procedures can be

changeable in locations in which the signi?cant feature of the
amino acid residue is its charge and the differing pK’ s of these

employed, particularly where it is desired to mutate a gene
such that predetermined restriction nucleotides or codons are

altered by substitution, deletion or insertion. Exemplary
methods of making such alterations are disclosed by Walder
et al. (Gene 42:133, 1986); Bauer et al. (Gene 37:73, 1985);
Craik (BioTechniques, Jan. 12-19, 1985); Smith et al. (Ge

50

changes can be considered “conservative” in particular envi
ronments.
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netic Engineering: Principles and Methods, Plenum Press,
1981); Kunkel (Proc. Natl. Acad. Sci. USA 82:488, 1985);
Kunkel et al. (Methods in Enzymol. 154.367, 1987). The
present invention thus encompasses any nucleic acid capable
of encoding a protein of the current invention.
The current invention provides for isolated polypeptides.

The effects of such substitutions can be calculated using
substitution score matrices such PAM120, PAM-200, and
PAM-250 as discussed in Altschul, (J. Mol. Biol. 219:55565

(1991)). Other such conservative substitutions, for example,
substitutions of entire regions having similar hydrophobicity
characteristics, are well known.
60

Naturally-occurring peptide variants are also encompassed
by the invention. Examples of such variants are proteins that
result from alternate mRNA splicing events or from pro

teolytic cleavage of the polypeptides described herein. Varia
tions attributable to proteolysis include, for example, differ

As used herein, the term “polypeptides” refers to a genus of

polypeptide or peptide fragments that encompass the amino
acid sequences identi?ed herein, as well as smaller frag
ments. Alternatively, a polypeptide may be de?ned in terms of

two amino acid residues are not signi?cant. Still other
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ences in the N- or C-termini upon expression in different
types of host cells, due to proteolytic removal of one or more

its antigenic relatedness to any peptide encoded by the nucleic

terminal amino acids from the polypeptides encoded by the

acid sequences of the invention. Thus, in one embodiment, a

sequences of the invention.

